NASDAQ$RNAM
Avidity Biosciences Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Avidity Biosciences reported Q3 2025, a net loss of $174.4M, diluted EPS of $-1.27.
For Q3 2025, Avidity Biosciences reported a net loss of $174.4M, diluted EPS of $-1.27. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.
- Net loss $174.4M.
- Diluted EPS $-1.27.
- Avidity Biosciences updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Avidity Biosciences · Revenue · Quarterly
$12.5M
Revenue by segment
Avidity Biosciences · $2.82M total across 1 segment · Q3 2023
- Collaboration revenue$2.82M—100.0%
Forward guidance
The filing discusses Avidity Biosciences's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Avidity Biosciences cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q3 2025
+1.3%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+8.2%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.5%
Q4 2023
Best reaction
-12.5%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q4 2025 | — | — | — | |
| Q3 2025 | +1.3% | +1.4% | +2.5% | |
| Q2 2025 | -2.7% | -2.8% | +6.1% | |
| Q1 2025 | -0.6% | +1.3% | -2.0% | |
| Q4 2024 | +5.4% | +1.7% | +11.9% | |
| Q3 2024 | -1.1% | -1.1% | -18.9% | |
| Q2 2024 | +6.2% | +2.6% | -2.9% | |
| Q1 2024 | -0.4% | +11.0% | +2.2% | |
| Q4 2023 | +19.5% | +23.1% | +66.6% | |
| Q3 2023 | -6.0% | — | — | |
| Q2 2023 | +6.0% | — | — | |
| Q1 2023 | +4.0% | — | — | |
| Q4 2022 | +5.6% | — | — | |
| Q3 2022 | +5.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.4% | — | — | |
| Q4 2021 | +0.9% | — | — | |
| Q3 2021 | -0.5% | — | — | |
| Q2 2021 | -1.4% | — | — | |
| Q1 2021 | -12.5% | — | — | |
| Q4 2020 | +7.5% | — | — | |
| Q3 2020 | -1.0% | — | — | |
| Q2 2020 | +1.9% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro